

# Dianne Nicol

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5531738/publications.pdf>

Version: 2024-02-01

102  
papers

2,164  
citations

279798

23  
h-index

265206

42  
g-index

103  
all docs

103  
docs citations

103  
times ranked

1828  
citing authors

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | Cell counts and maps in the larval central nervous system of the ascidian <i>Ciona intestinalis</i> (L). <i>Journal of Comparative Neurology</i> , 1991, 309, 415-429.  | 1.6  | 223       |
| 2  | Development of the central nervous system of the larva of the ascidian, <i>Ciona intestinalis</i> L. <i>Developmental Biology</i> , 1988, 130, 737-766.   | 2.0  | 197       |
| 3  | Development of the central nervous system of the larva of the ascidian, <i>Ciona intestinalis</i> L. <i>Developmental Biology</i> , 1988, 130, 721-736.   | 2.0  | 145       |
| 4  | An analysis of the number and composition of the synaptic populations formed by photoreceptors of the fly. <i>Journal of Comparative Neurology</i> , 1982, 207, 29-44.  | 1.6  | 109       |
| 5  | A review of the key issues associated with the commercialization of biobanks. <i>Journal of Law and the Biosciences</i> , 2014, 1, 94-110.  | 1.6  | 87        |
| 6  | Predicting intention to biobank: a national survey. <i>European Journal of Public Health</i> , 2012, 22, 139-144.   | 0.3  | 84        |
| 7  | Has the biobank bubble burst? Withstanding the challenges for sustainable biobanking in the digital era. <i>BMC Medical Ethics</i> , 2016, 17, 39.  | 2.4  | 81        |
| 8  | Global Public Perceptions of Genomic Data Sharing: What Shapes the Willingness to Donate DNA and Health Data?. <i>American Journal of Human Genetics</i> , 2020, 107, 743-752.  | 6.2  | 76        |
| 9  | Trust in genomic data sharing among members of the general public in the UK, USA, Canada and Australia. <i>Human Genetics</i> , 2019, 138, 1237-1246.   | 3.8  | 69        |
| 10 | The Impact of Commercialisation and Genetic Data Sharing Arrangements on Public Trust and the Intention to Participate in Biobank Research. <i>Public Health Genomics</i> , 2015, 18, 160-172.                                    | 1.0  | 60        |
| 11 | Understanding public reactions to commercialization of biobanks and use of biobank resources. <i>Social Science and Medicine</i> , 2016, 162, 79-87.  | 3.8  | 53        |
| 12 | Community Engagement for Big Epidemiology: Deliberative Democracy as a Tool. <i>Journal of Personalized Medicine</i> , 2014, 4, 459-474.  | 2.5  | 49        |
| 13 | Global citizen deliberation on genome editing. <i>Science</i> , 2020, 369, 1435-1437.   | 12.6 | 47        |
| 14 | Ethics review for international data-intensive research. <i>Science</i> , 2016, 351, 1399-1400.   | 12.6 | 44        |
| 15 | Benefit sharing and biobanking in Australia. <i>Public Understanding of Science</i> , 2012, 21, 534-555.  | 2.8  | 43        |
| 16 | Patent landscaping for life sciences innovation: toward consistent and transparent practices. <i>Nature Biotechnology</i> , 2013, 31, 202-206.  | 17.5 | 42        |
| 17 | Understanding the impact of commercialization on public support for scientific research: Is it about the funding source or the organization conducting the research?. <i>Public Understanding of Science</i> , 2011, 20, 347-366. | 2.8  | 40        |
| 18 | Demonstrating trustworthiness when collecting and sharing genomic data: public views across 22 countries. <i>Genome Medicine</i> , 2021, 13, 92.  | 8.2  | 39        |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 19 | Trust, patents and public perceptions: the governance of controversial biotechnology research. <i>Nature Biotechnology</i> , 2006, 24, 1352-1354.   | 17.5 | 38        |
| 20 | Predicting Public Attitudes Toward Gene Editing of Germlines: The Impact of Moral and Hereditary Concern in Human and Animal Applications. <i>Frontiers in Genetics</i> , 2018, 9, 704.                         | 2.3  | 38        |
| 21 | Regulation in the number of fly photoreceptor synapses: The effects of alterations in the number of presynaptic cells. <i>Journal of Comparative Neurology</i> , 1982, 207, 45-60.                              | 1.6  | 36        |
| 22 | Commercialisation of biotechnology: public trust and research. <i>International Journal of Biotechnology</i> , 2004, 6, 116.  | 1.2  | 31        |
| 23 | Toward better governance of human genomic data. <i>Nature Genetics</i> , 2021, 53, 2-8.   | 21.4 | 31        |
| 24 | Public reaction to direct-to-consumer online genetic tests: Comparing attitudes, trust and intentions across commercial and conventional providers. <i>Public Understanding of Science</i> , 2015, 24, 731-750. | 2.8  | 29        |
| 25 | Members of the public in the USA, UK, Canada and Australia expressing genetic exceptionalism say they are more willing to donate genomic data. <i>European Journal of Human Genetics</i> , 2020, 28, 424-434.   | 2.8  | 29        |
| 26 | Using TRIPS flexibilities to facilitate access to medicines. <i>Bulletin of the World Health Organization</i> , 2013, 91, 533-539.  | 3.3  | 26        |
| 27 | Identifying public expectations of genetic biobanks. <i>Public Understanding of Science</i> , 2017, 26, 671-687.  | 2.8  | 25        |
| 28 | Precision medicine: drowning in a regulatory soup?. <i>Journal of Law and the Biosciences</i> , 2016, 3, 281-303.   | 1.6  | 18        |
| 29 | Key challenges in bringing CRISPR-mediated somatic cell therapy into the clinic. <i>Genome Medicine</i> , 2017, 9, 85.  | 8.2  | 17        |
| 30 | Marking Shifts in Human Research Ethics in the Development of Biobanking. <i>Public Health Ethics</i> , 2015, 8, 63-71.   | 1.0  | 16        |
| 31 | Capital, trust & consultation: Databanks and regulation in Australia. <i>Critical Public Health</i> , 2005, 15, 349-358.  | 2.4  | 15        |
| 32 | Reactions to the National Academies/Royal Society Report on Heritable Human Genome Editing. <i>CRISPR Journal</i> , 2020, 3, 332-349.   | 2.9  | 15        |
| 33 | Breast Cancer Gene Research and Medical Practices. , 0, , .   |      | 15        |
| 34 | Australia: regulating genomic data sharing to promote public trust. <i>Human Genetics</i> , 2018, 137, 583-591.   | 3.8  | 14        |
| 35 | Patents and Medical Biotechnology: An Empirical Analysis of Issues Facing the Australian Industry. <i>SSRN Electronic Journal</i> , 0, , .  | 0.4  | 13        |
| 36 | A Role for Research Ethics Committees in Exchanges of Human Biospecimens Through Material Transfer Agreements. <i>Journal of Bioethical Inquiry</i> , 2014, 11, 301-306.  | 1.5  | 12        |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 37 | New avenues within community engagement: addressing the ingenuity gap in our approach to health research and future provision of health care. <i>Journal of Responsible Innovation</i> , 2014, 1, 321-328. | 4.9  | 12        |
| 38 | Are patents for methods of medical treatment contrary to the ordre public and morality or "generally inconvenient"?. <i>Journal of Medical Ethics</i> , 2004, 30, 470-475.                                 | 1.8  | 11        |
| 39 | Genomics in research and health care with Aboriginal and Torres Strait Islander peoples. <i>Monash Bioethics Review</i> , 2015, 33, 203-209.   | 0.8  | 11        |
| 40 | International Divergence in Gene Patenting. <i>Annual Review of Genomics and Human Genetics</i> , 2019, 20, 519-541.   | 6.2  | 11        |
| 41 | Identifying the nature and extent of public and donor concern about the commercialisation of biobanks for genomic research. <i>European Journal of Human Genetics</i> , 2021, 29, 503-511.                 | 2.8  | 10        |
| 42 | Public Trust, Intellectual Property and Human Genetic Databanks: The Need to Take Benefit Sharing Seriously. <i>Journal of International Biotechnology Law</i> , 2006, 3, .                                | 0.1  | 9         |
| 43 | To share or not to share is the question. <i>Applied &amp; Translational Genomics</i> , 2014, 3, 116-119.  | 2.1  | 9         |
| 44 | Are the gene-patent storm clouds dissipating? A global snapshot. <i>Nature Biotechnology</i> , 2015, 33, 347-352.  | 17.5 | 9         |
| 45 | Streamlining ethical review of data intensive research. <i>BMJ</i> , The, 2016, 354, i4181.  | 6.0  | 9         |
| 46 | Consent insufficient for data release. <i>Science</i> , 2019, 364, 445-446.  | 12.6 | 9         |
| 47 | Human genetic research databases and biobanks: towards uniform terminology and Australian best practice. <i>Journal of Law &amp; Medicine</i> , 2008, 15, 538-55.  | 0.0  | 9         |
| 48 | Pharmacogenetic testing: legal considerations for consent, privacy and disclosure. <i>Personalized Medicine</i> , 2008, 5, 155-161.  | 1.5  | 8         |
| 49 | Continental drift? Do European clinical genetic testing laboratories have a patent problem?. <i>European Journal of Human Genetics</i> , 2019, 27, 997-1007.   | 2.8  | 8         |
| 50 | Public reactions to direct-to-consumer genetic health tests: A comparison across the US, UK, Japan and Australia. <i>European Journal of Human Genetics</i> , 2020, 28, 339-348.                           | 2.8  | 8         |
| 51 | Return of genomic results does not motivate intent to participate in research for all: Perspectives across 22 countries. <i>Genetics in Medicine</i> , 2022, 24, 1120-1129.                                | 2.4  | 8         |
| 52 | Patenting nature—a comparative perspective. <i>Journal of Law and the Biosciences</i> , 2018, 5, 550-589.  | 1.6  | 7         |
| 53 | Provenance and risk in transfer of biological materials. <i>PLoS Biology</i> , 2018, 16, e2006031.   | 5.6  | 7         |
| 54 | Balancing Innovation and Access to Healthcare through the Patent System — An Australian Perspective. <i>Public Health Genomics</i> , 2005, 8, 228-234.   | 1.0  | 6         |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 55 | Gene patentsâ€”more evidence needed, but policymakers must act. <i>Nature Biotechnology</i> , 2007, 25, 388-389.   | 17.5 | 6         |
| 56 | Human genetic databanks in Australia: indications of inconsistency and confusion. <i>New Genetics and Society</i> , 2008, 27, 311-321.   | 1.2  | 6         |
| 57 | Bespoke regulation for bespoke medicine? A comparative analysis of bioprinting regulation in Europe, the USA and Australia. <i>Journal of 3D Printing in Medicine</i> , 2021, 5, 155-167.      | 2.0  | 6         |
| 58 | Do patents impede the provision of genetic tests in Australia?. <i>Australian Health Review</i> , 2013, 37, 281.   | 1.1  | 6         |
| 59 | Strategies for dissemination of university knowledge. <i>Health Law Journal</i> , 2008, 16, 207-35.  | 0.2  | 6         |
| 60 | Balancing access to pharmaceuticals with patent rights. <i>Monash Bioethics Review</i> , 2003, 22, S50-S62.  | 0.8  | 5         |
| 61 | The continuing saga of patents and nonâ€”invasive prenatal testing. <i>Prenatal Diagnosis</i> , 2019, 39, 441-447.   | 2.3  | 5         |
| 62 | Beyond Open Source: Patents, Biobanks and Sharing. , 2013, , 191-208.  |      | 5         |
| 63 | Personalised medicine in the genome era. <i>Journal of Law &amp; Medicine</i> , 2013, 20, 577-94.  | 0.0  | 5         |
| 64 | Navigating the molecular diagnostic patent landscape. <i>Expert Opinion on Therapeutic Patents</i> , 2008, 18, 461-472.  | 5.0  | 4         |
| 65 | Ethics and Governance of Stem Cell Banks. <i>Methods in Molecular Biology</i> , 2017, 1590, 99-112.  | 0.9  | 4         |
| 66 | A Scenario-Based Methodology for Analyzing the Ethical, Legal, and Social Issues in Genomic Data Sharing. <i>Journal of Empirical Research on Human Research Ethics</i> , 2020, 15, 355-364.   | 1.3  | 4         |
| 67 | Integrating Public Participation, Transparency and Accountability Into Governance of Marketing Authorisation for Genome Editing Products. <i>Frontiers in Political Science</i> , 2021, 3, .   | 1.7  | 4         |
| 68 | Directâ€”toâ€”consumer genetic testing â€” a regulatory nightmare?. <i>Medical Journal of Australia</i> , 2013, 198, 501-502.  | 1.7  | 3         |
| 69 | Opening the dam: patent pools, innovation and access to essential medicines. , 0, , 235-262.   |      | 3         |
| 70 | Standards for Biobank Access and Intellectual Property. , 2012, , .  |      | 3         |
| 71 | An ethico-legal assessment of intellectual property rights and their effect on COVID-19 vaccine distribution: an Australian case study. <i>Journal of Law and the Biosciences</i> , 2022, 9, . | 1.6  | 3         |
| 72 | The Innovation Pool in Biotechnology: The Role of Patents in Facilitating Innovaiton. <i>SSRN Electronic Journal</i> , 0, , .  | 0.4  | 2         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 73 | The ethics of genome editing in the clinic: A dose of realism for healthcare leaders. <i>Healthcare Management Forum</i> , 2017, 30, 159-163.                               | 1.4 | 2         |
| 74 | The Regulatory Role of Patents in Innovative Health Research and Its Translation from the Laboratory to the Clinic. , 2021, , 139-147.                                      |     | 2         |
| 75 | Whither Patent Use without Authorisation in Australia?. <i>Federal Law Review</i> , 2008, 36, 331-362.  | 0.4 | 2         |
| 76 | Body ownership and research. <i>Journal of Law &amp; Medicine</i> , 2013, 21, 323-9.  | 0.0 | 2         |
| 77 | Collaborative Licensing in Biotechnology: A Survey of Knowledge, Experience, and Attitudes in Australia. <i>Biotechnology Law Report</i> , 2010, 29, 465-483.               | 0.1 | 1         |
| 78 | Another Missed Opportunity to Reform Compulsory Licensing and Crown Use in Australia. <i>SSRN Electronic Journal</i> , 0, , .   | 0.4 | 1         |
| 79 | Compulsory licensing of patents. <i>Information and Communications Technology Law</i> , 2016, 25, 247-271.  | 1.5 | 1         |
| 80 | Mitochondrial Donation: The Australian Story. <i>Journal of Bioethical Inquiry</i> , 2020, 17, 161-164.   | 1.5 | 1         |
| 81 | The Regulatory Framework for Protection of Genetic Privacy in Australia. , 2013, , 283-321.   |     | 1         |
| 82 | Genetic Testing and Protection of Genetic Privacy. , 2011, , 235-255.   |     | 1         |
| 83 | Strong Patent Rights, Weak Patent Standards and Innovation in Biomedicine. , 2009, , .  |     | 1         |
| 84 | A Role for Virtual Biotechnology Companies in Drug Discovery and Development?. <i>Journal of Commercial Biotechnology</i> , 2013, 19, .                                     | 0.4 | 1         |
| 85 | Unconventional Practice, "Innovative" Interventions and the National Law. <i>Journal of Law &amp; Medicine</i> , 2020, 27, 574-589.   | 0.0 | 1         |
| 86 | Human gene patents: under whose control?. <i>Medical Journal of Australia</i> , 2003, 179, 181-182.   | 1.7 | 0         |
| 87 | Implementing values-based governance for a new bioresource model. <i>Journal of Law and the Biosciences</i> , 2017, 4, 404-411.   | 1.6 | 0         |
| 88 | Regulating innovative health technologies: dialectics, dialogics, and the case of faecal microbiota transplants. <i>Law, Innovation and Technology</i> , 2020, 12, 284-296. | 3.2 | 0         |
| 89 | The Regulation of Human Germline Genome Modification in Australia. , 2020, , 543-567.   |     | 0         |
| 90 | Reply to C.D. Richter. <i>European Journal of Human Genetics</i> , 2020, 28, 537-538.   | 2.8 | 0         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 91  | Cooperative Intellectual Property in Biotechnology. Script Ed, 2007, 4, 136-151.  | 0.8 | 0         |
| 92  | Whither Patent Use without Authorisation in Australia?. Federal Law Review, 2008, 36, 331-362.  | 0.4 | 0         |
| 93  | Time to Get Serious about Privacy Policies: The Special Case of Genetic Privacy. Federal Law Review, 2014, 42, 1-32.  | 0.4 | 0         |
| 94  | Time to Get Serious about Privacy Policies: The Special Case of Genetic Privacy. Federal Law Review, 2014, 42, 1-32.  | 0.4 | 0         |
| 95  | Submission in Response to the Australian Productivity Commission's Inquiry into IP Arrangements Draft Report. SSRN Electronic Journal, 0, , .   | 0.4 | 0         |
| 96  | Why We Should Simplify Transfers Of Research Materials. , 2018, , .   |     | 0         |
| 97  | Gene Editing Clinical Trials Could Slip through Australian Regulatory Cracks. Journal of Law & Medicine, 2019, 27, 274-283.   | 0.0 | 0         |
| 98  | Terms of Engagement: Transfer of Biological Materials for Research in Australia. Journal of Law & Medicine, 2019, 27, 338-354.  | 0.0 | 0         |
| 99  | Australian Perspectives on the Ethical and Regulatory Considerations for Responsible Data Sharing in Response to the COVID-19 Pandemic. Journal of Law & Medicine, 2020, 27, 829-838. | 0.0 | 0         |
| 100 | Don Chalmers: His Contributions to Legal Research and Education, Health Law, and Research Ethics, Locally and Globally. Journal of Law & Medicine, 2020, 28, 289-297.                 | 0.0 | 0         |
| 101 | Pathways, Processes and Protections: Australia's Clinical and Direct-to-Consumer Genetic Testing Spaces. Journal of Law & Medicine, 2021, 28, 370-388.                                | 0.0 | 0         |
| 102 | Regulatory Capitalism, Business Models and the Knowledge Economy. , 2008, , .   |     | 0         |